The Value of 18-FDG PET CT in Soft Tissue Sarcoma.
10.4055/jkoa.2010.45.3.216
- Author:
Jeung Il KIM
1
;
Jong Seok OH
;
Kuen Tak SUH
;
Tae Yong MOON
;
In Sook LEE
;
Kyung Un CHOI
;
Seong Jang KIM
Author Information
1. Department of Orthopedic Surgery, College of Medicine, Pusan National University, Pusan, Korea. osteokim@yahoo.co.kr
- Publication Type:Original Article
- Keywords:
PET-CT;
soft tissue sarcoma;
SUV
- MeSH:
Discrimination (Psychology);
Humans;
Neoplasm Metastasis;
Recurrence;
ROC Curve;
Sarcoma
- From:The Journal of the Korean Orthopaedic Association
2010;45(3):216-221
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Recently, there have been many attempts to use PET-CT for the diagnosis of metastasis of soft tissue tumors and for differentiating benign tumors from malignant tumors. In this study, we wanted to evaluate the efficacy of 18-FDG PET CT in soft tissue tumors. MATERIALS AND METHODS: Patients (n=64) with suspected malignant soft tissue tumor had 18-FDG PET CT scans. This included 15 cases of benign soft tissue tumor, 34 cases of malignant soft tissue tumor and 15 cases of inflammatory lesions. All patients went through surgical treatment after PET-CT imaging was done, and all dissected tissues were biopsied. For semiquantitive analysis, SUVmax(Maximal standard uptake value) was measured, and SUVmax was determined using ROC analysis, the Kruskal-Wallis test and the Mann-Whitney test. RESULTS: Using 18-FDG PET CT it was possible to differentiate benign from malignant tumor using SUVmax values. But, discrimination between different grades of tumor was not possible. Also discrimination between malignant tumors and inflammatory lesions was not possible. CONCLUSION: PET-CT can be considered as a useful nuclear imaging method that can detect local recurrence and distant metastasis of soft tissue sarcoma and can differentiate benign from malignant tumors. But PET-CT results must be interpreted carefully in diagnoses when there is inflammatory disease or a suspected lesion present.
